•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH) said its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The company also appointed Jan Stern Reed as Chair of the Board, effective immediately.
Vance has served as Interim CEO since October 2025 and will continue to serve on the Board as an executive member.
In a statement, Jan Stern Reed, newly appointed Chair of AVITA Medical’s Board, said the Board unanimously concluded that Cary Vance is the right leader to serve as CEO on a permanent basis following a thorough search process conducted with an international executive search firm.
Reed said that over the past six months, Vance has demonstrated “decisive leadership” by stabilizing the business, sharpening the company’s strategic focus, and rebuilding confidence and enthusiasm among employees, customers, and shareholders.
Vance said it has been a privilege to serve as Interim Chief Executive Officer and that he is honored to continue in the role on a permanent basis. He cited feedback from clinicians at meetings including Boswick and the American Burn Association, saying the company’s products are driving clinically validated improvements in patient outcomes and improving recovery.
Vance added that AVITA is focused on scaling adoption, supporting more clinicians in delivering better outcomes, and translating that momentum into consistent performance.
Dr. Michael Tarnoff, Chair of the Board’s Human Capital and Compensation Committee, said Reed is an experienced independent director who has served on the Board since 2021 and most recently served as Lead Independent Director since October. Tarnoff said Reed will continue to work closely with Vance and the rest of the Board to support AVITA Medical’s strategic priorities and continued growth.
Cary Vance has served on AVITA Medical’s Board of Directors since 2023 and was appointed Chairman in 2025. The company described him as a healthcare executive with 30 years of experience driving value creation and commercializing innovative medical technologies.
AVITA said Vance previously served as President and Chief Executive Officer of PhotoniCare, Inc., Titan Medical Inc., OptiScan Biomedical, MyoScience, Hansen Medical, and XCath. Earlier in his career, he held senior leadership roles at Teleflex, Covidien, and GE HealthCare.
Jan Stern Reed has served on the AVITA Medical Board since 2021 and brings more than 35 years of legal and business management experience in the healthcare industry, both as an executive leader and board member.
The company said Reed served as Lead Independent Director since October 2025, a role the Board discontinued at the same time as her appointment to the independent Chair position.
AVITA Medical said it will host a conference call and Q&A to discuss its first quarter 2026 earnings results on Thursday, May 14, 2026. The company said the call and webcast will be held at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time).
Details are available on the company’s website at: https://ir.avitamedical.com/events-and-presentations
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
